[PDF][PDF] Down-titration of adalimumab and etanercept in psoriatic patients: a multicentre observational study
S Piaserico, P Gisondi, C De Simone… - Acta Dermato …, 2016 - iris.univr.it
Acta Dermato-Venereologica, 2016•iris.univr.it
RESULTS A total of 85 patients (55 (65%) males, 30 (35%) females; mean age 51±13.6
years) were included in the study. Patients' mean psoriasis duration was 21.7±10.8 years
(range 2–63.9 years), mean baseline C-reactive protein (CRP) was 1±2.6 mg/l, mean
baseline body mass index (BMI) was 26.4±3.5 kg/m2. Twenty-eight of the patients (33%)
smoked or had a history of smoking. No statistical differences were found in these variables
between the patients treated with etanercept (n= 54) and those receiving adalimumab (n …
years) were included in the study. Patients' mean psoriasis duration was 21.7±10.8 years
(range 2–63.9 years), mean baseline C-reactive protein (CRP) was 1±2.6 mg/l, mean
baseline body mass index (BMI) was 26.4±3.5 kg/m2. Twenty-eight of the patients (33%)
smoked or had a history of smoking. No statistical differences were found in these variables
between the patients treated with etanercept (n= 54) and those receiving adalimumab (n …
RESULTS
A total of 85 patients (55 (65%) males, 30 (35%) females; mean age 51±13.6 years) were included in the study. Patients’ mean psoriasis duration was 21.7±10.8 years (range 2–63.9 years), mean baseline C-reactive protein (CRP) was 1±2.6 mg/l, mean baseline body mass index (BMI) was 26.4±3.5 kg/m2. Twenty-eight of the patients (33%) smoked or had a history of smoking. No statistical differences were found in these variables between the patients treated with etanercept (n= 54) and those receiving adalimumab (n= 31). As shown in Fig. 1, the cumulative relapse risk in the etanercept and adalimumab-treated patients was
iris.univr.it
以上显示的是最相近的搜索结果。 查看全部搜索结果